Publications

Effects of high schizotypy on control of eye movements: modulation by antipsychotic drugs and nicotine. 49th Annual Meeting of the American College of Neuropsychopharmacology. Hollywood, FL: ACNP, 2010

Deakin, J.F.W., Schmechtig, A., Dourish, C.T., Craig, K.J., Dawson, G.R., Williams, S.C.R., Lees, J., Wilkinson, L. and Ettinger U. (2010).

A validation of cognitive biomarkers for the early identification of cognitive enhancing agents in schizotypy: a three-centre double-blind placebo-controlled study. European Neuropsychopharmacology, Jul;22(7):469-81.

Koychev, I., McMullen, K., Lees, J., Dadhiwala, R., Grayson, L., Perry, C., Schmechtig, A., Walters, J., Craig, K.J., Dawson, G.R., Dourish, C.T., Ettinger, U., Wilkinson, L., Williams, S.C.R., Deakin, J.F.W. and Barkus, E. (2011).

Effects of risperidone, amisulpride and nicotine on eye movement control and their modulation by schizotypy. Psychopharmacology Epub 2013 February 22.

Schmechtig A., Lees J., Grayson L., Craig K. J., Dadhiwala R., Dawson G.R., Deakin J.F.W., Dourish C.T., Koychev I, McMullen K, Migo E.M., Perry C., Wilkinson L., Morris R., Williams S.C.R., Ettinger U. (2013).

The effects of ketamine and risperidone on eye movement control in healthy volunteers. Translational Psychiatry, Dec 10;3:e334.

Schmechtig A., Lees J., Perkins A., Altavilla A., Craig K.J., Dawson G.R., Deakin J.F.William, Dourish C.T., Evans L.H., Koychev I., Weaver K., Smallman R., Walters J., Wilkinson L.S., Morris R., Williams S.C.R. and Ettinger U. (2013).

The effects of sibutramine on the microstructure of eating behaviour and energy expenditure in obese women. Journal of Psychopharmacology, 24, 99-109. Epub 2008 Aug 28.

Halford, J.C.G., Boyland E.J., Cooper S.J., Dovey T.M., Huda M.S.B., Dourish C.T., Dawson G.R. and Wilding, J.P.H. (2010).

Serotonin receptor ligands and the treatment of obesity. Current Opinion in Investigational Drugs, 5, 377-388.

Vickers, S.P. and Dourish, C.T. (2004). Serotonin receptor ligands and the treatment of obesity. Current Opinion in Investigational Drugs, 5, 377-388.

« Previous PageNext Page »